NASDAQ:BMRN
$117.27
(
0.248%
)
Friday, 27th Jan 2023
BioMarin Pharmaceutical Inc. Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $100.52 | $117.77 | Friday, 27th Jan 2023 BMRN stock ended at $117.27. This is 0.248% more than the trading day before Thursday, 26th Jan 2023. During the day the stock fluctuated 0.82% from a day low at $116.81 to a day high of $117.77. |
| 90 days | $80.53 | $117.77 | |
| 52 weeks | $70.73 | $117.77 |
Historical BioMarin Pharmaceutical Inc. prices
| Date | Open | High | Low | Close | Volume |
| 2023-01-27 | $117.00 | $117.77 | $116.81 | $117.27 | 1 217 204 |
| 2023-01-26 | $116.00 | $117.11 | $115.03 | $116.98 | 1 336 524 |
| 2023-01-25 | $114.60 | $116.59 | $114.39 | $116.03 | 2 450 322 |
| 2023-01-24 | $111.45 | $114.02 | $111.26 | $113.82 | 1 202 216 |
| 2023-01-23 | $110.40 | $111.55 | $110.20 | $111.45 | 1 173 358 |
| 2023-01-20 | $109.47 | $111.03 | $109.29 | $110.75 | 1 338 400 |
| 2023-01-19 | $110.47 | $110.47 | $109.10 | $109.20 | 1 148 300 |
| 2023-01-18 | $111.31 | $112.05 | $110.33 | $110.69 | 1 107 348 |
| 2023-01-17 | $111.55 | $112.99 | $111.02 | $111.75 | 1 554 900 |
| 2023-01-13 | $112.25 | $114.80 | $111.87 | $112.72 | 1 582 120 |
| 2023-01-12 | $110.50 | $113.65 | $110.01 | $113.57 | 1 723 544 |
| 2023-01-11 | $111.23 | $112.70 | $109.14 | $111.15 | 1 699 156 |
| 2023-01-10 | $107.26 | $111.97 | $106.99 | $111.40 | 2 864 771 |
| 2023-01-09 | $109.83 | $110.25 | $105.95 | $107.10 | 2 526 703 |
| 2023-01-06 | $108.17 | $109.29 | $106.90 | $108.71 | 2 205 800 |
| 2023-01-05 | $107.00 | $107.59 | $105.77 | $106.86 | 1 794 348 |
| 2023-01-04 | $103.69 | $106.93 | $102.26 | $106.92 | 2 710 984 |
| 2023-01-03 | $103.00 | $103.33 | $100.52 | $100.61 | 1 025 099 |
| 2022-12-30 | $101.92 | $103.57 | $100.95 | $103.49 | 889 346 |
| 2022-12-29 | $101.87 | $103.45 | $101.67 | $102.44 | 794 578 |
| 2022-12-28 | $101.98 | $103.10 | $101.30 | $101.74 | 904 491 |
| 2022-12-27 | $104.50 | $104.85 | $102.03 | $102.16 | 760 711 |
| 2022-12-23 | $105.01 | $105.56 | $103.87 | $104.34 | 696 038 |
| 2022-12-22 | $104.61 | $105.70 | $103.99 | $105.66 | 1 335 845 |
| 2022-12-21 | $105.94 | $107.08 | $104.53 | $104.62 | 1 457 763 |
| 2022-12-20 | $105.92 | $106.75 | $105.56 | $106.30 | 997 223 |
| 2022-12-19 | $108.63 | $108.63 | $105.81 | $106.61 | 1 225 988 |
| 2022-12-16 | $107.73 | $108.92 | $107.13 | $108.63 | 2 537 038 |
| 2022-12-15 | $108.00 | $109.56 | $106.81 | $108.61 | 1 614 617 |
| 2022-12-14 | $106.93 | $109.25 | $106.51 | $108.38 | 1 672 054 |
| 2022-12-13 | $107.08 | $107.91 | $106.55 | $107.08 | 1 765 332 |
| 2022-12-12 | $102.25 | $106.35 | $102.25 | $106.26 | 1 856 434 |
| 2022-12-09 | $104.23 | $104.46 | $102.28 | $102.33 | 815 513 |
| 2022-12-08 | $103.99 | $104.62 | $103.17 | $104.39 | 723 024 |
| 2022-12-07 | $101.09 | $103.94 | $101.09 | $103.69 | 1 319 198 |
| 2022-12-06 | $102.97 | $103.44 | $101.17 | $102.22 | 889 357 |
| 2022-12-05 | $105.00 | $105.34 | $103.25 | $103.53 | 994 347 |
| 2022-12-02 | $103.00 | $106.72 | $102.75 | $105.56 | 2 220 168 |
| 2022-12-01 | $100.71 | $103.06 | $99.29 | $103.02 | 2 013 886 |
| 2022-11-30 | $98.51 | $101.28 | $97.85 | $100.98 | 2 493 125 |
| 2022-11-29 | $99.01 | $99.56 | $97.00 | $97.12 | 1 304 257 |
| 2022-11-28 | $97.25 | $100.30 | $96.52 | $98.66 | 2 591 319 |
| 2022-11-25 | $97.46 | $98.43 | $96.31 | $96.92 | 727 779 |
| 2022-11-23 | $95.09 | $99.74 | $94.91 | $97.79 | 4 635 440 |
| 2022-11-22 | $88.99 | $91.63 | $88.01 | $91.18 | 1 620 250 |
| 2022-11-21 | $88.67 | $88.86 | $87.98 | $88.51 | 734 460 |
| 2022-11-18 | $88.04 | $88.76 | $87.65 | $88.13 | 501 999 |
| 2022-11-17 | $85.66 | $87.92 | $85.63 | $87.11 | 639 146 |
| 2022-11-16 | $86.69 | $86.69 | $85.51 | $86.23 | 613 362 |
| 2022-11-15 | $85.30 | $87.44 | $84.78 | $86.60 | 855 042 |
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
